mune reaction. In this case, procedures designed to increase lymphocyte reactivity nonspecifically or to produce localized responses at the tumour sites are more clearly indicated. Finally, administration of tumour antigen preparations such as isolated membrane fractions should be viewed with caution since the experience from experimental studies is that this may produce an enhancing response.
Professor P Alexander (Chester Beatty Research Institute, Belmont, Sutton, Surrey) Immunotherapy of Experimental Tumours 'Escape' ofautologous tumours: The possible ways by which some immunological procedures may be of therapeutic benefit must be discussed in relation to the basic problem of 'escape', i.e. why malignant cells with tumour-specific antigens in their membranes are successful and not rejected like allografts of normal tissues. A number of different escape mechanisms have been postulated: (1) That the tumour-bearing host has an impaired immune system. It is now abundantly clear that any immune defect in cancer patients is a consequence of advanced disease and not its cause. While immunosuppression may in some instances facilitate the induction of tumours, immunosuppression is not an essential component of successful tumour growth. (2) That tumour-bearing animals are specifically tolerant to the tumour-specific antigens. Recent work has shown that in most animal tumours the host is capable of recognizing the tumour-specific antigens of its own autologous tumour even though the immune reaction which results from this recognition is obviously inadequate. (3) That tumours are protected from destruction by cytotoxic lymphocytes, as a result of being coated with a non-complement-binding antibody which masks the tumour-specific antigens without affecting the growth rate of the cells so coated. We have been quite unable, in human and in animal tumours, to find evidence that the cells of autologous tumours are blocked in this way by antibody. To question the existence of protection by antibody is not in conflict with the well-established phenomenon of immunological enhancement because the mechanisms are quite different.
Consideration of infectious diseases provides abundant evidence for the view that escape from immune defences of the host can occur without the intervention of specific mechanisms such as those listed above. Infectious agents persist because the immune responses of the body are not expressed equally at all sites and the effectiveness of the different effector mechanisms is limited by physiological and immunological factors. In the destruction of antigenic cells in vivo three mechanisms have to be considered: antibody acting in conjunction with complement; macrophages which have become specifically sensitized; and cytotoxic lymphoid cells. Cytotoxic antibodies: Circulating antibody, and particularly the very cytotoxic macroglobulins, are, because of their size, confined largely to the vascular compartments. Their concentration at extravascular sites is much lower than in the blood. This explains why antibodies directed against tumour-specific antigens are of relatively little value for immunotherapy. Such antisera are only able to destroy cells which are readily accessible. Specifically immune macrophages: Specifically cytotoxic macrophages are produced as the result of interaction with immune lymphoid cells; possibly the latter produce an antigenically specific cytophilic factor which coats the macrophages. These immune macrophages are capable of protecting the peritoneal cavity and possibly the lung. They are not, however, very effective in attacking subcutaneous tumours unless ancillary inflammatory reactions are induced which promote the entrance of macrophages. It is possible that the retardation of tumour growth which has been achieved in some systems by treating animals bearing tumours with nonspecific stimulants of the reticuloendothelial system, such as BCG or Corynebacterium parvum, functions by increasing the availability of macrophages. Cytotoxic lymphocytes: Tumours at subcutaneous sites are vulnerable to attack by cytotoxic lymphoid cells; the most effective of these are immunoblasts; they have the capacity to traverse capillary beds and thus reach extravascular sites and they have been shown to be directly cytotoxic. Immunoblasts are released into the efferent lymph of a stimulated node between 3 and 10 days after antigenic stimulation. However, growing tumours interfere with the release of such cells from draining nodes; possibly the continual bombardment of nodes by antigens causes a local situation such that the immunoblasts no longer leave the node. This 'paralysis' of the node does not interfere with the production of antibodies but prevents subcutaneous tumours from being assailed by imnumoblasts. This phenomenon may also explain why in an animal bearing an antigenic subcutaneous tumour this may grow apparently unopposed, while other sites such as the peritoneal cavity or the vascular space are resistant to tumour challenge.
The value of irradiated tumour autografts: The lymph node 'paralysis' can be by-passed by immunizing distant nodes with tumour cells that have been rendered non-viable by prior exposure to X-rays. Nodes stimulated in this way function normally and discharge immunoblasts. This provides a possible rationale for the therapeutic effects that have been observed following autografting with irradiated tumours in some animal systems. It must be stressed, however, that this procedure has only been effective when the amount of viable tumour which needed to be eradicated was small. Treatment with immunoblasts: Another way of overcoming the lymph node 'paralysis' is to inject immunoblasts derived by immunizing 'donor' animals with a piece of the tumour to be treated. Following such immunization the immunoblasts are collected from the lymph of such animals and injected into the tumour-bearing animal. This procedure, again, has been found to produce an arrest of tumour growth in certain carefully selected animal systems. The large number of immunoblasts needed to produce a beneficial effect would appear to make this procedure impractical for clinical trial at the present time.
Conclusion
In conclusion, it must be emphasized that immunological procedures can be shown to be of therapeutic benefit in carefully manipulated animal situations but as yet we have no indication that any such procedures would be useful in tumour problems encountered in man. One thing which appears to be clear is that the immuno-logical procedures known to us at present can only achieve the eradication of relatively few cells and that as far as we can see immunotherapy can at best only assist established methods of treatment after these have achieved removal of the vast bulk of the tumour.
Dr K D Bagshawe (EdgarLaboratory, Fulham Hospital, London W6)
Choriocarcinoma
During the past decade interest has focused on the proposition that tumours may have antigens which are, to some extent, foreign to their host and that these antigens may provide a target for therapeutic attack. The failure attending this approach, so far, has been attributed to a variety of mechanisms and notably to the weakness of tumour-associated antigens. In the case of choriocarcinoma it was evident that strong antigenic differences might be involved and if so, should not immunotherapy be successful here?
Placental choriocarcinoma is an allograft which arises from the trophoblast of one individual and invades another. The host often has a humoral response to antigens which the tumour inherits from the male parent and there is often a good mononuclear cell reaction to the tumour. Yet the fact of the occurrence of the tumour indicates the inadequacy of the host-versustumour reaction alone to control it. A marked cellular reaction does, however, favour the response to chemotherapy (Elston 1969) and where chemotherapy has failed to eliminate the tumour me have tried to augment the immunological contribution.
The methods used included repeated active nonspecific immunization with BCG, repeated active specific immunization with tissues from the patient's husband and passive immunization with heterologous antisera raised to the husband's leukocyte antigens. Immunotherapy has been initiated when there was only minimal residual disease. No convincing success can be claimed for these immunotherapeutic procedures (Bagshawe & Golding 1970) .
Failure to get encouraging results with choriocarcinoma clearly requires us to look more closely into our assumptions about the host-tumour relationship. Current theory leads us to expect that the most strongly antigenic tumours should be eliminated and it also leads us to expect that antigens expressed by the host, but not expressed by the tumour, would not influence host-tumour interaction. This has been studied in choriocarcinoma and in patients with other forms of trophoblastic neoplasia with respect to the HL-A, ABO and Rh systems.
